Literature DB >> 21840325

Disruption of CD38 gene enhances cardiac functions by elevating serum testosterone in the male null mice.

Lu Gan1, Wei Jiang, Yun-Fei Xiao, Lin Deng, Lun-Da Gu, Zhi-Yun Guo, Zhi-Chao Zhou, Dan Wu, Hong-Bo Xin.   

Abstract

AIMS: Gender-related phenotypes in the cardiovascular system have been observed in various genetically modified mice. Here, we report that cardiac functions are significantly improved only in male CD38-null mice and we explore the potential mechanisms of the sexual dimorphism mediated by CD38 deficiency. MAIN
METHODS: Cardiac functions of mice were measured by pressure-volume conductance catheter technique and echocardiography. Serum sex steroids were determined by radioimmunoassay. Relative mRNA levels of myocardial contractile-associated proteins in cardiomyocytes were analyzed by real-time PCR analysis. To clarify the effects of testosterone on the sexual dimorphism, flutamide, an androgen receptor antagonist, was subcutaneously infused into the male null mice for 6 weeks with an osmotic mini-pump. KEY
FINDINGS: The myocardial contractility, contraction and relaxation velocities were significantly enhanced only in male CD38-null mice, in which the levels of serum testosterone were markedly elevated. The elevated testosterone levels in the null mice were correlated to an obvious decrease in expression of androgen receptor and dramatic increases in expressions of major genes involved in myocardial contraction, including ryanodine receptor type 2 (RyR2), sarcoplasmic reticular Ca(2+) ATPase (SERCA2) and Na(+)/Ca(2+)-exchanger protein 1 (NCX1), and α myosin heavy chain (α-MHC). More importantly, all of the alternations that were observed in the male null mice were almost completely restored by flutamide administration. SIGNIFICANCE: Elevated serum level of testosterone in the male CD38(-/-) mice enhances cardiac functions through upregulation of major calcium regulatory proteins, which improve our understanding on sex disparities and molecular mechanisms in the incidence and manifestation of heart diseases.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21840325     DOI: 10.1016/j.lfs.2011.07.020

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  7 in total

Review 1.  Role of NAD+ and mitochondrial sirtuins in cardiac and renal diseases.

Authors:  Kathleen A Hershberger; Angelical S Martin; Matthew D Hirschey
Journal:  Nat Rev Nephrol       Date:  2017-02-06       Impact factor: 28.314

Review 2.  The CD38 glycohydrolase and the NAD sink: implications for pathological conditions.

Authors:  Julianna D Zeidler; Kelly A Hogan; Guillermo Agorrody; Thais R Peclat; Sonu Kashyap; Karina S Kanamori; Lilian Sales Gomez; Delaram Z Mazdeh; Gina M Warner; Katie L Thompson; Claudia C S Chini; Eduardo Nunes Chini
Journal:  Am J Physiol Cell Physiol       Date:  2022-02-09       Impact factor: 4.249

3.  Sexually dimorphic effects of SARM1 deletion on cardiac NAD+ metabolism and function.

Authors:  Hina Lateef Nizami; Keaton E Minor; Ying Ann Chiao; Christine M Light; Chi Fung Lee
Journal:  Am J Physiol Heart Circ Physiol       Date:  2022-09-02       Impact factor: 5.125

Review 4.  CD38: A Potential Therapeutic Target in Cardiovascular Disease.

Authors:  Wanyun Zuo; Na Liu; Yunhong Zeng; Yaozhong Liu; Biao Li; Keke Wu; Yunbin Xiao; Qiming Liu
Journal:  Cardiovasc Drugs Ther       Date:  2021-08       Impact factor: 3.727

Review 5.  Androgen-Regulated Cardiac Metabolism in Aging Men.

Authors:  Genaro Barrientos; Paola Llanos; Carla Basualto-Alarcón; Manuel Estrada
Journal:  Front Endocrinol (Lausanne)       Date:  2020-05-15       Impact factor: 5.555

6.  CD38 Deficiency Protects the Heart from Ischemia/Reperfusion Injury through Activating SIRT1/FOXOs-Mediated Antioxidative Stress Pathway.

Authors:  Xiao-Hui Guan; Xiao-Hong Liu; Xuan Hong; Ning Zhao; Yun-Fei Xiao; Ling-Fang Wang; Ling Tang; Kai Jiang; Yi-Song Qian; Ke-Yu Deng; Guangju Ji; Mingui Fu; Hong-Bo Xin
Journal:  Oxid Med Cell Longev       Date:  2016-07-31       Impact factor: 6.543

Review 7.  Novel strategies halt cardiovascular, diabetes, and cancer strips.

Authors:  Chun-Song Hu; Qing-Hua Wu; Da-Yi Hu; Tengiz Tkebuchava
Journal:  Chronic Dis Transl Med       Date:  2017-07-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.